332 related articles for article (PubMed ID: 34835135)
1. Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects.
Gillot C; Favresse J; Maloteau V; Dogné JM; Douxfils J
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835135
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
Favresse J; Gillot C; Di Chiaro L; Eucher C; Elsen M; Van Eeckhoudt S; David C; Morimont L; Dogné JM; Douxfils J
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372570
[TBL] [Abstract][Full Text] [Related]
3. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
4. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
[TBL] [Abstract][Full Text] [Related]
5. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
6. Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand.
Putcharoen O; Wacharapluesadee S; Chia WN; Paitoonpong L; Tan CW; Suwanpimolkul G; Jantarabenjakul W; Ruchisrisarod C; Wanthong P; Sophonphan J; Chariyavilaskul P; Wang LF; Hemachudha T
PLoS One; 2021; 16(2):e0246864. PubMed ID: 33577615
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
[TBL] [Abstract][Full Text] [Related]
8. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
Valcourt EJ; Manguiat K; Robinson A; Lin YC; Abe KT; Mubareka S; Shigayeva A; Zhong Z; Girardin RC; DuPuis A; Payne A; McDonough K; Wang Z; Gasser R; Laumaea A; Benlarbi M; Richard J; Prévost J; Anand SP; Dimitrova K; Phillipson C; McGeer A; Gingras AC; Liang C; Petric M; Sekirov I; Morshed M; Finzi A; Drebot M; Wood H
Microbiol Spectr; 2021 Dec; 9(3):e0088621. PubMed ID: 34787495
[TBL] [Abstract][Full Text] [Related]
9. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.
Grenache DG; Ye C; Bradfute SB
J Appl Lab Med; 2021 Mar; 6(2):491-495. PubMed ID: 33098417
[TBL] [Abstract][Full Text] [Related]
10. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
Morinaga Y; Tani H; Terasaki Y; Nomura S; Kawasuji H; Shimada T; Igarashi E; Saga Y; Yoshida Y; Yasukochi R; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Fujimura T; Ishida Y; Oishi K; Yamamoto Y
Microbiol Spectr; 2021 Dec; 9(3):e0056021. PubMed ID: 34851163
[TBL] [Abstract][Full Text] [Related]
11. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays.
Nandakumar V; Profaizer T; Lozier BK; Elgort MG; Larragoite ET; Williams ESCP; Solis-Leal A; Lopez JB; Berges BK; Planelles V; Rychert J; Slev PR; Delgado JC
Arch Pathol Lab Med; 2021 Oct; 145(10):1212-1220. PubMed ID: 34181714
[TBL] [Abstract][Full Text] [Related]
13. Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects.
Cristiano A; Nuccetelli M; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S
Int Immunopharmacol; 2021 Dec; 101(Pt B):108215. PubMed ID: 34649115
[TBL] [Abstract][Full Text] [Related]
14. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
[TBL] [Abstract][Full Text] [Related]
15. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
[TBL] [Abstract][Full Text] [Related]
16. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.
Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903
[TBL] [Abstract][Full Text] [Related]
17. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.
von Rhein C; Scholz T; Henss L; Kronstein-Wiedemann R; Schwarz T; Rodionov RN; Corman VM; Tonn T; Schnierle BS
J Virol Methods; 2021 Feb; 288():114031. PubMed ID: 33275926
[TBL] [Abstract][Full Text] [Related]
18. A flow cytometry-based assay to measure neutralizing antibodies against SARS-CoV-2 virus.
Pscheidt VM; de Souza PO; Fazolo T; Modena JLP; Simeoni C; Teixeira D; Silva NB; Dos Santos KB; Júnior LR; Bonorino C
Cytometry A; 2024 Jun; 105(6):446-457. PubMed ID: 38624015
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
Rathe JA; Hemann EA; Eggenberger J; Li Z; Knoll ML; Stokes C; Hsiang TY; Netland J; Takehara KK; Pepper M; Gale M
J Infect Dis; 2021 Apr; 223(7):1120-1131. PubMed ID: 33367830
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]